CVS Caremark Corporation (CVS) reported on Wednesday that it has agreed to acquire infusion services and nutrition business Coram LLC for $2.1 billion.
CVS will purchase Coram from Apria Healthcare Group Inc in a deal that will likely close in the first quarter of 2014. CVS said that this acquisition is expected to add $1.4 billion to revenue in the first year and 3 to 5 cents per share in 2015. This purchase is in-line with the company strategy of focusing on core businesses that will drive growth.
Jon Roberts, President of CVS Caremark Pharmacy Services said in a statement: “Bringing together CVS Caremark’s unique range of specialty pharmacy services with Coram’s infusion capabilities will expand our competitive offerings in the specialty arena. Infusion will be a valuable component of our broad specialty pharmacy offering going forward. Our comprehensive services will enable us to streamline care management for patients as well as their physicians, leading to better health outcomes while avoiding unnecessary costs.”
Top 10 Clean Energy Companies To Invest In 2015: Cerus Corporation(CERS)
Cerus Corporation, a biomedical products company, engages in the development and commercialization of the INTERCEPT Blood System. The company?s INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. It markets the INTERCEPT system for platelets and plasma primarily in Europe, the Russian Federation, and the Middle East. The company is also developing INTERCEPT Blood System for red blood cells or red blood cell system, which is designed to inactivate blood-borne pathogens in donated red blood cells for transfusion. Cerus Corporation has collaboration agreements with Baxter International, Inc.; and BioOne Corporation, as well as the United States Armed Forces. The company was founded in 1991 and is based in Concord, California.
Advisors' Opinion:- [By Seth Jayson]
Cerus (Nasdaq: CERS ) is expected to report Q1 earnings on April 30. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Cerus's revenues will expand 15.0% and EPS will remain in the red.
Top Prefered Companies To Own In Right Now: Dell Inc.(DELL)
Dell Inc. provides integrated technology solutions in the information technology (IT) industry worldwide. It designs, develops, manufactures, markets, sells, and supports mobility and desktop products, including notebooks, workstations, tablets, smartphones, and desktop PCs, as well as servers and networking products. The company offers storage solutions, including storage area networks, network-attached storage, direct-attached storage, and various backup systems. It also provides IT and business services comprising transactional services, such as support, managed deployment, enterprise installation, and configuration services; outsourcing services, including data center and systems management, network management, life cycle application development and management, and business process outsourcing services; and project-based services consisting of IT infrastructure, applications, business process, and business consulting services. In addition, the company offers third-part y software products comprising operating systems, business and office applications, anti-virus and related security software, and entertainment software; and peripheral products, such as printers, televisions, notebook accessories, mouse, keyboards, networking and wireless products, and digital cameras. Further, it provides financial services, including originating, collecting, and servicing customer receivables related to the purchase of its products and third-party technology products. The company sells its products and services directly through its sales representatives, telephone-based sales, and online sales; and through retailers, third-party solution providers, system integrators, and third-party resellers. It serves corporate businesses, law enforcement agencies, small and medium businesses, consumers, and public institutions that include government, education, and healthcare organizations. Dell Inc. was founded in 1984 and is headquartered in Round Rock, Texas.
Advisors' Opinion:- [By Adam Levine-Weinberg]
As each week goes by, the situation at Dell (NASDAQ: DELL ) looks more and more like a repeat of the Titanic. There's an iceberg ahead, but nobody seems capable of doing anything about it. As Michael Dell and Carl Icahn struggle for control of this once-great company, ordinary shareholders' interests are increasingly being left by the wayside. As a result, Dell stock has been slowly losing altitude.
- [By Alex Dumortier, CFA]
Dell: The heat is on
I have continued covering Michael Dell and Silver Lake Partners' plan to take Dell (NASDAQ: DELL ) private, but had come to the conclusion that the duo had this deal sewn up despite activist investor Carl Icahn's gesticulations. We're now in the home stretch, with a shareholder vote scheduled less than two weeks from now, and it appears that I may have underestimated the impact of Mr. Icahn's efforts. - [By Rick Aristotle Munarriz]
Alamy Companies can make brilliant moves, but there are also times when things don't work out quite as planned. From an underwhelming iPhone event to Pandora's new CEO, here's a rundown of the week's best and worst moves in the business world. Apple (AAPL) -- Loser Shares of the consumer tech giant had rallied heading into Tuesday's iPhone event, but the love didn't last. The stock began to sell off while Apple was still presenting its updated smartphones. There were no smartwatches, no high-def smart TVs, and no magical unicorns offered up at the presentation. The market was also unimpressed to find that the cheaper iPhone that everyone was hoping would make inroads into Android's 80 percent global market share wound up being just $100 cheaper than the new iPhone 5s. Apple only updates its iPhones annually, so it was also a letdown to see the company once again fail to produce phones with screens larger than four inches. Yes, Apple is spicing up the shell colors across both new iPhone lines, but the actual screens are too small compared to the larger Android devices that many consumers are choosing these days. Pandora (P) -- Winner The leading music streaming service had been searching for a new CEO for months, and it finally found one. Brian McAndrews -- who at one time ran digital marketing powerhouse aQuantive before selling it to Microsoft (MSFT) in a $6 billion deal -- will take control of the leading media platform that serves up 1.35 billion hours a month to its more than 72 million active listeners. It's a smart hire. Pandora didn't need a big terrestrial radio guru. Pandora isn't about content programming. It already has the technology in place that serves up timely music recommendations and adapts to a listeners preferences. Pandora's major challenge remains to monetize its growing airplay, and that's where McAndrews is the perfect fit for a fast-growing company that's just starting to impress marketers. The Dow -- Loser The Dow Jones Industr
- [By David Chulak]
Haven�� you ever wanted to know whether Warren Buffett shops at Walmart (WMT) and Dollar General (DG) or whether he uses Geico insurance? I know a great new product is coming to the market, but has Bill Gates been using an iPhone? Does Michael Dell use Dell (DELL) products? Does Exxon (XOM) CEO Rex Tillerson wear a ski mask if he�� low on gas and has to pull into a Shell (RDS.A) oil gas station? Does anyone in the Walton family actually shop at Walmart? Do they ever go into a Whole Foods (WFM) or Kroger (KR)? These questions, as slightly humorous as they may be, may actually be more important to know than some of the nonsense that gets delivered to us through Wall Street.
Top Prefered Companies To Own In Right Now: Embraer SA (EMBR3)
Embraer SA is a Brazil-based holding company primarily engaged in the manufacture of aircrafts. The Company�� business activities are divided into three business segments: Commercial Aviation; Defense and Security Business, and Executive Aviation. The Commercial Aviation segment is involved in the development, production and sale of commercial jets, as well as in the provision of support services, with emphasis on the regional aviation industry and aircraft leasing. The Defense and Security Business segment mainly includes the research, development, production and modification of defense aircrafts as well systems and software design. Through the Executive Aviation segment, the Company is active in the development, production and sale of business jets, provision of support services related to this sector of the market and aircraft leasing. The Company has subsidiaries, affiliated companies and representative offices in Brazil, the United States, France, Holland and China, among others. Advisors' Opinion:- [By Lyubov Pronina]
Most emerging-market stocks fell as Samsung Electronics Co.�� earnings missed estimates and planemaker Embraer SA (EMBR3) posted a surprise loss. Turkish stocks capped the biggest weekly loss since June after policy makers raised borrowing costs.
- [By Ney Hayashi]
The Ibovespa dropped for a third day as planemaker Embraer SA (EMBR3) led losses among exporters on speculation that a strengthening local currency will erode revenue from outside Brazil.
Top Prefered Companies To Own In Right Now: Advanced Cell Technology, Inc.(ACTC)
Advanced Cell Technology, Inc., a biotechnology company, focuses on the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. Its embryonic stem cell research programs include cellular reprogramming, reduced complexity program, and stem cell differentiation research programs. The company?s cellular reprogramming involves in the development of therapies based on the use of genetically identical pluripotent stem cells generated by its cellular reprogramming technologies. Advanced Cell Technology, Inc. also generates stable cell lines with particular focus on blood lineage and vascular epithelial cell lines from hemangioblast cells. In addition, it is developing an autologous myoblast transplantation therapy to restore cardiac function in patients with advanced heart disease. The company?s stem cell-based therapy would provide treatment for a range of acute and chronic degenerative diseases. Further, it deve lops adult stem cell-based products that are specifically targeted at therapies for heart and other cardiovascular diseases. The company is headquartered in Marlborough, Massachusetts.
Advisors' Opinion:- [By John Udovich]
As the the year comes to end, there is still a steady flow of interesting news coming from small cap biotech stocks like Organovo Holdings Inc (NYSEMKT: ONVO), Advanced Cell Technology, Inc (OTCMKTS: ACTC) and TNI BioTech (OTCMKTS: TNIB)�plus still largely private biotech companies like Genocea Biosciences (NASDAQ: GNCA), Retrophin (OTCMKTS: RTRX), Auspex Pharmaceuticals (NASDAQ: ASPX) and GlycoMimetics (NASDAQ: GLYC) who have filed to become the next potentially hot biotech IPOs���presumably some time early�next year. Just consider the following biotech news:
- [By CRWE]
Today, ACTC surged (+1.96%) up +0.0014 at $.0730 with 1,679,139 shares in play thus far (ref. google finance Delayed: 12:31PM EDT July 26, 2013).
Advanced Cell Technology, Inc. previously reported the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company�� three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of remaining two patients in the third cohort of each of the three clinical trials. The decision follows an interim review by the DSMB six weeks after the first patient was treated in the third cohort of each trial. ACT will proceed with screening and enrollment for the patients who, in keeping with trial protocol, will be injected with 150,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
- [By CRWE]
Today, ACTC has shed (-1.05%) down -0.0008 at $.0751 with 2,338,132 shares in play thus far (ref. google finance Delayed: 11:55AM EDT July 22, 2013), but don�� let this get you down.
Advanced Cell Technology, Inc. previously reported the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company�� three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of remaining two patients in the third cohort of each of the three clinical trials. The decision follows an interim review by the DSMB six weeks after the first patient was treated in the third cohort of each trial. ACT will proceed with screening and enrollment for the patients who, in keeping with trial protocol, will be injected with 150,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs).
- [By John Udovich]
Summer and the slow news for the market that usually comes with it�is over with and both stem cell researchers or small� cap stem cell stocks like Advanced Cell Technology, Inc (OTCBB: ACTC), Neuralstem, Inc (NYSEMKT: CUR), NeoStem Inc (NASDAQ: NBS), International Stem Cell Corp (OTCMKTS: ISCO)�and BioRestorative Therapies (OTCBB: BRTX) having news for investors and traders alike. Consider the following:
No comments:
Post a Comment